{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T04:29:33Z","timestamp":1782016173442,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejca.2021.02.028","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T13:56:48Z","timestamp":1617026208000},"page":"382-394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Pembrolizumab plus eribulin in hormone-receptor\u2013positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase \u2161 trial"],"prefix":"10.1016","volume":"148","author":[{"given":"Jos\u00e9 M.","family":"P\u00e9rez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Llombart-Cussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"L\u00f3pez-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8746-2096","authenticated-orcid":false,"given":"Jos\u00e9 L.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8314-0241","authenticated-orcid":false,"given":"Lourdes","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Cara\u00f1ana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"de. la Cruz S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"M\u00e1rquez V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ruiz Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sampayo-Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-6746","authenticated-orcid":false,"given":"Miguel \u00c1.","family":"Segu\u00ed-Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Soberino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Malfettone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.02.028_bib1","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"24","author":"Rugo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.02.028_bib2","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/S0140-6736(16)32419-9","article-title":"Advances in the treatment of advanced oestrogen-receptor-positive breast cancer","volume":"389","author":"Turner","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.02.028_bib3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","article-title":"Annual hazard rates of recurrence for breast cancer during 24 Years of follow-up: results from the International breast cancer study group trials I to V","volume":"34","author":"Colleoni","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.02.028_bib4","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.02.028_bib5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.02.028_bib6","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.18632\/oncotarget.7235","article-title":"Activation of the PD-1\/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis","volume":"7","author":"Black","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2021.02.028_bib7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-018-0126-6","article-title":"Checkpoint blockade in the treatment of breast cancer: current status and future directions","volume":"119","author":"Wein","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2021.02.028_bib8","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.02.028_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.02.028_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.02.028_bib11","doi-asserted-by":"crossref","first-page":"v859","DOI":"10.1093\/annonc\/mdz394.010","article-title":"LBA21 - KEYNOTE-119: phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)","volume":"30","author":"Cort\u00e9s","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.02.028_bib12","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.02.028_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.02.028_bib15","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.02.028_bib16","series-title":"FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer","year":"2020"},{"key":"10.1016\/j.ejca.2021.02.028_bib17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.02.028_bib18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2021.02.028_bib19","unstructured":"KEYTRUDA 25 mg\/mL concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) n.d. https:\/\/www.medicines.org.uk\/emc\/product\/2498\/smpc#gref (accessed December 29, 2020)."},{"key":"10.1016\/j.ejca.2021.02.028_bib20","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1158\/1078-0432.CCR-16-3066","article-title":"Immuno-oncology clinical trial design: limitations, challenges, and opportunities","volume":"23","author":"Baik","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.02.028_bib21","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.02.028_bib22","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1002\/cam4.2281","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals","volume":"8","author":"Guo","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2021.02.028_bib23","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","article-title":"High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study","volume":"27","author":"Miyoshi","year":"2020","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejca.2021.02.028_bib24","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2020.3524","article-title":"Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor\u2013positive, ERBB2-negative metastatic breast cancer: a randomized clinical trial","volume":"6","author":"Tolaney","year":"2020","journal-title":"JAMA Oncology"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921001258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921001258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:32:31Z","timestamp":1760733151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921001258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":23,"alternative-id":["S0959804921001258"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.02.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab plus eribulin in hormone-receptor\u2013positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase \u2161 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}